Online inquiry

IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7836MR)

This product GTTS-WQ7836MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7836MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12422MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ10815MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ9176MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ6665MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ10735MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ5435MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ2358MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ13304MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW